A guided choice for treatment of hormone receptor-positive advanced breast cancer

Research output: Contribution to journalArticle

Abstract

Expression of hormone receptor and HER2 identify different breast cancer subtypes with distinct biology, clinical behavior, and treatment sensitivity. Hormone receptor positive (HR+) tumors are largely dependent on hormones, and endocrine manipulation is the cornerstone of therapy. In the case of concomitant HER2 overexpression, HER2 blockade is critical to allow for endocrine responsiveness. Several strategies to block or interfere with hormones are available, including ovarian function suppression (premenopause), selective estrogen receptor modulators (SERMs), aromatase inhibitors, and estrogen receptor downregulators. The more efficacious endocrine agents are progressively incorporated into the adjuvant treatment; therefore, the optimal strategy for patients who eventually relapse is largely influenced by their prior exposure to adjuvant therapies. Patients with HR+/HER2 negative disease might benefit from sequential use of all available endocrine agents, delaying the use of chemotherapy. The combination of endocrine therapy plus anti-HER2 agents is a valid option for selected patients with HR+/HER2+ disease not immediately requiring chemotherapy. New strategies to overcome endocrine resistance, such as co-targeting the mTOR pathway, are promising.

Original languageEnglish
Pages (from-to)15-20
Number of pages6
JournalHot Topics in Oncology
Issue number8
Publication statusPublished - 2011

Fingerprint

Hormones
Breast Neoplasms
Premenopause
Selective Estrogen Receptor Modulators
Therapeutics
Drug Therapy
Aromatase Inhibitors
Estrogen Receptors
Recurrence
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

@article{ea0f9d8155f14955b6ad6be033563217,
title = "A guided choice for treatment of hormone receptor-positive advanced breast cancer",
abstract = "Expression of hormone receptor and HER2 identify different breast cancer subtypes with distinct biology, clinical behavior, and treatment sensitivity. Hormone receptor positive (HR+) tumors are largely dependent on hormones, and endocrine manipulation is the cornerstone of therapy. In the case of concomitant HER2 overexpression, HER2 blockade is critical to allow for endocrine responsiveness. Several strategies to block or interfere with hormones are available, including ovarian function suppression (premenopause), selective estrogen receptor modulators (SERMs), aromatase inhibitors, and estrogen receptor downregulators. The more efficacious endocrine agents are progressively incorporated into the adjuvant treatment; therefore, the optimal strategy for patients who eventually relapse is largely influenced by their prior exposure to adjuvant therapies. Patients with HR+/HER2 negative disease might benefit from sequential use of all available endocrine agents, delaying the use of chemotherapy. The combination of endocrine therapy plus anti-HER2 agents is a valid option for selected patients with HR+/HER2+ disease not immediately requiring chemotherapy. New strategies to overcome endocrine resistance, such as co-targeting the mTOR pathway, are promising.",
author = "Valentina Guarneri and Pierfranco Conte",
year = "2011",
language = "English",
pages = "15--20",
journal = "Hot Topics in Oncology",
issn = "1973-9656",
publisher = "FBCommunication srl",
number = "8",

}

TY - JOUR

T1 - A guided choice for treatment of hormone receptor-positive advanced breast cancer

AU - Guarneri, Valentina

AU - Conte, Pierfranco

PY - 2011

Y1 - 2011

N2 - Expression of hormone receptor and HER2 identify different breast cancer subtypes with distinct biology, clinical behavior, and treatment sensitivity. Hormone receptor positive (HR+) tumors are largely dependent on hormones, and endocrine manipulation is the cornerstone of therapy. In the case of concomitant HER2 overexpression, HER2 blockade is critical to allow for endocrine responsiveness. Several strategies to block or interfere with hormones are available, including ovarian function suppression (premenopause), selective estrogen receptor modulators (SERMs), aromatase inhibitors, and estrogen receptor downregulators. The more efficacious endocrine agents are progressively incorporated into the adjuvant treatment; therefore, the optimal strategy for patients who eventually relapse is largely influenced by their prior exposure to adjuvant therapies. Patients with HR+/HER2 negative disease might benefit from sequential use of all available endocrine agents, delaying the use of chemotherapy. The combination of endocrine therapy plus anti-HER2 agents is a valid option for selected patients with HR+/HER2+ disease not immediately requiring chemotherapy. New strategies to overcome endocrine resistance, such as co-targeting the mTOR pathway, are promising.

AB - Expression of hormone receptor and HER2 identify different breast cancer subtypes with distinct biology, clinical behavior, and treatment sensitivity. Hormone receptor positive (HR+) tumors are largely dependent on hormones, and endocrine manipulation is the cornerstone of therapy. In the case of concomitant HER2 overexpression, HER2 blockade is critical to allow for endocrine responsiveness. Several strategies to block or interfere with hormones are available, including ovarian function suppression (premenopause), selective estrogen receptor modulators (SERMs), aromatase inhibitors, and estrogen receptor downregulators. The more efficacious endocrine agents are progressively incorporated into the adjuvant treatment; therefore, the optimal strategy for patients who eventually relapse is largely influenced by their prior exposure to adjuvant therapies. Patients with HR+/HER2 negative disease might benefit from sequential use of all available endocrine agents, delaying the use of chemotherapy. The combination of endocrine therapy plus anti-HER2 agents is a valid option for selected patients with HR+/HER2+ disease not immediately requiring chemotherapy. New strategies to overcome endocrine resistance, such as co-targeting the mTOR pathway, are promising.

UR - http://www.scopus.com/inward/record.url?scp=84857070203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857070203&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84857070203

SP - 15

EP - 20

JO - Hot Topics in Oncology

JF - Hot Topics in Oncology

SN - 1973-9656

IS - 8

ER -